Sunday, September 30, 2012

NVA237 / Seebri (glycopyrronium bromide) inhalation capsules approved in Japan for COPD treatment

Seebri inhalation capusle has received the first regulatory approval  in Japan. Seebri is a once daily LAMA intended for the treatment of COPD. Current guidelines recommend use of LAMA as a first line therapy in moderate to severe COPD patients. Seebri would compete with Boehringer Ingelheim's Spiriva (tiotropium). In an open label trial Seebri demonstrated comparable efficacy and safety when compared to tiotropium.